Issue 98

double-blind randomised

Legitimacy in the absence of double-blind randomised clinical trials

A double-blind randomised clinical trial prevents bias when evaluating patient outcomes, validating the research. It is referred to as a double-blind study, as neither the researcher nor the patient knows who has received an intervention and who has received a placebo.

However, it is almost impossible to conduct double-blind studies in psychotherapy, and consequently psychedelic-assisted therapy, due to the patient’s active involvement in the therapy component.

The client will only access psilocybin at a licensed service centre during an administration session in the presence of a licensed facilitator. An optional integration session will be offered to a client after the administration session.

READ MORE

KETAMINE INFUSIONS FOR TREATMENT-RESISTANT DEPRESSION

In a real-world study of 242 people suffering with treatment-resistant depression, 38% saw remission after 10 ketamine infusions.

Read More

US$900,000 GRANT FOR THERAPIST TRAINING PROGRAMME

Heffter Research Institute awarded the grant to researchers at Johns Hopkins, Yale and NYU to build out a postdoctoral fellowship.

Read More

BUSINESS AND INVESTMENT

Awakn partners with Catalent to accelerate MDMA onset.

LSD -assisted therapy for anxiety and depression.

Algenon receives approval for DMT stroke study.

Nirvana develops efficient MDMA production method.

Optimi completes Canada’s largest psilocybe cubensis harvest.

Revitalist and Wake Network enter joint veterans venture.

SCIENCE AND RESEARCH

Psilocybin’s effect on the serotonin system of people with autism.

Meta-analysis of ketamine infusions for depression.

Ketamine in the treatment of Helsmoortel-VanDerAa syndrome.

Neural mechanisms of imagery under psilocybin.

The Psychedelics as Medicine Report

The Psychedelics as Medicine Report positions organisations in front of regulators, researchers and investors.

With over 60,000 downloads, the industry leading publication contains proprietary market data and insights to identify emerging opportunities.

Previous partners include COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact [email protected]

CONTACT FORM

REGULATION AND LEGISLATION

San Francisco lawmakers approve decriminalisation resolution.

Move to ban psychedelic medicine in Australia.

ARTICLES OF INTEREST

The link between physical and mental health.

Circadian rhythm disruptions linked to mental health.

Psilocybin-assisted therapy in couples.

Mental health and social conditions.

What do we really know about mental illness?

PSYCH is looking forward to attending ICPR Conference in Amsterdam next week. If you are going it would be great to connect.

OPEN has given PSYCH subscribers a €30 discount code: psychlive30